AGN 223575

Drug Profile

AGN 223575

Alternative Names: AGN-223575

Latest Information Update: 29 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 01 Jan 2016 Allergan completes a phase II trial in Dry eyes in USA (Ophthalmic) (NCT02435914)
  • 01 Jun 2015 Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (NCT02435914)
  • 01 May 2015 Allergan plans a phase II trial for Dry eyes in USA (NCT02435914)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top